Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MabSpace and Ambrx to Collaborate on Antibody Drug Conjugates

publication date: Jan 6, 2017
MabSpace Biosciences of Suzhou will collaborate with San Diego's Ambrx to discover and develop multiple novel antibody drug conjugates for oncology. Both companies are known for their drug discovery platforms. Two years ago, Ambrx was bought for an undisclosed sum by two active China life science companies, Fosun Pharma and WuXi Apptec. MabSpace has developed an immune tolerance breaking technology, and Ambrx claims small-molecule-like specificity for its ADCs. Both companies have partnered drug candidates with outside pharmas. The two companies will develop the molecules jointly, sharing the cost and rights of the resulting ADC products. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital